This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo
Clinical Summary

Severe influenza: favipiravir plus oseltamivir vs oseltamivir alone

Takeaway

  • In patients with severe influenza infection, favipiravir and oseltamivir combination therapy may be associated with greater antiviral effects and faster clinical recovery than oseltamivir monotherapy.

Why this matters

  • No previous studies have compared the effects of favipiravir and oseltamivir combination therapy with oseltamivir monotherapy in the treatment of severe influenza infection.

Study design

  • Study included 168 patients with influenza who were treated with favipiravir and oseltamivir combination therapy (n=40) and oseltamivir monotherapy (n=128) using data from 2 separate prospective studies.
  • Main outcomes: clinical improvement (decrease of 2 categories on a 7-category ordinal scale) and viral RNA detectability over time.
  • Funding: National Key Research and Development Program of China and others.

Key results

  • Combination group vs monotherapy group showed higher clinical improvement on day 14 (adjusted sub-hazard ratio [sHR], 2.06; 95% CI, 1.30-3.26; P=.0021).
  • On day 10, the proportion of patients with undetectable viral RNA was higher in the combination group than that in the monotherapy group (67.5% vs 21.9%; P<.01).
  • No significant differences were observed between both the groups in mortality and other outcomes.

Limitations

  • Small number of patients in both the group.

References


YOU MAY ALSO LIKE